# A Comprehensive Study of Xenon Anesthesia in Patients with Locally Advanced Gastric Cancer: A Single-Center Study

**Authors:** Natalia Yunusova, Vladimir Faltin, Dmitry Svarovsky, Olga Cheremisina, Elena E. Sereda, Alexandra Augustinovich, Evgeny Usynin, Marina Stakheyeva, Gelena Kakurina, Marina Vusik, Natalia Popova, Viktoria Velikaya, Sergey Afanasiev

PMC · DOI: 10.3390/medsci14010146 · Medical Sciences · 2026-03-18

## TL;DR

This study compares xenon-based anesthesia with sevoflurane in gastric cancer surgery, finding xenon reduces recovery time and postoperative pain.

## Contribution

The study introduces xenon + dexmedetomidine anesthesia as a novel method with better postoperative outcomes in gastric cancer surgery.

## Key findings

- Xenon + DMM anesthesia reduced awakening time, extubation time, and narcotic use compared to sevoflurane.
- Xenon anesthesia was associated with fewer postoperative complications and nausea/vomiting.
- Mathematical models using clinical parameters and anesthesia type accurately predicted severe complications and pain.

## Abstract

Objective: The objective of this study was to choose the optimal anesthesia method for gastric cancer patients undergoing surgery with lymph node dissection. Materials and Methods: The study included 53 patients with stage T1-4aN0-3M0 gastric cancer, who underwent radical surgery with xenon and dexmedetomidine (DMM) anesthesia in combination with epidural analgesia (main group, 27 patients) or with sevorflurane anesthesia in combination with epidural analgesia (comparison group, 26 patients). All patients underwent monitoring of hemodynamic parameters, blood coagulation system, thromboelastometry, and inflammation and metabolic parameters (interleukins, hormones and glucose levels), with an assessment of complications according to the Clavien-Dindo classification and the intensity of postoperative pain. Results: Awakening and extubation times, narcotic analgesic consumption, and Numeric Rating Scale pain scores were lower in the xenon + DMM group than in the sevoflurane group (p < 0.05). The overall number of patients experiencing complications did not differ significantly between anesthesia types; however, significant differences were found in the total number of complications (p = 0.003), the number of complications according to Clavien-Dindo I (p = 0.043) and II (p = 0.019), and the incidence of postoperative nausea and vomiting (p = 0.042). Conclusions: The BIS monitoring data obtained showed a sufficient level of anesthesia depth during surgery in both groups; however, post-anesthesia depression persisted longer in patients in sevoflurane group. Mathematical models for predicting Clavien-Dindo IIIb-V complications and severe postoperative pain syndrome are characterized by high sensitivity and specificity. They include simple clinical and laboratory parameters as well as type of anesthesia as predictors. The limitations of predictive models are also discussed in the article.

## Linked entities

- **Chemicals:** xenon (PubChem CID 23991), dexmedetomidine (PubChem CID 5311068), sevoflurane (PubChem CID 5206)
- **Diseases:** gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Psen1 (presenilin 1) [NCBI Gene 19164] {aka Ad3h, PS-1, PS1, S182}, F13A1 (coagulation factor XIII A chain) [NCBI Gene 2162] {aka F13A}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, Cd14 (CD14 antigen) [NCBI Gene 12475], IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, GPHA2 (glycoprotein hormone subunit alpha 2) [NCBI Gene 170589] {aka A2, GPA2, ZSIG51}, Gm12551 (perilipin 2 pseudogene) [NCBI Gene 101055843], F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, KCNK2 (potassium two pore domain channel subfamily K member 2) [NCBI Gene 3776] {aka K2p2.1, TPKC1, TREK, TREK-1, TREK1, hTREK-1c}, Trem2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 83433] {aka TREM-2, Trem2a, Trem2b, Trem2c}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, KCNK9 (potassium two pore domain channel subfamily K member 9) [NCBI Gene 51305] {aka BIBARS, K2p9.1, KT3.2, TASK-3, TASK3, TASK32}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}
- **Diseases:** blood coagulation (MESH:D001778), multiple organ failure (MESH:D009102), lupus nephritis (MESH:D008181), Cancer (MESH:D009369), T1-4aN0-3M0 (MESH:C538397), neurological injury (MESH:D020196), hypoxia (MESH:D000860), pulmonary embolism (MESH:D011655), chronic disease anemia (MESH:D002908), blood loss (MESH:D016063), Severe Pain Syndrome (MESH:D045169), postoperative delirium (MESH:D000071257), hyperglycemia (MESH:D006943), hyperthermia (MESH:D005334), Clavien-Dindo I-IIIa complications (MESH:C565554), thrombosis (MESH:D013927), inflammation (MESH:D007249), failure (MESH:D051437), vomiting (MESH:D014839), pain syndrome (MESH:C538101), iron deficiency (MESH:D000090463), bleeding (MESH:D006470), injury to (MESH:D014947), tauopathy (MESH:D024801), acidosis (MESH:D000138), acute cerebrovascular accident (MESH:D020521), depression (MESH:D003866), death (MESH:D003643), -Dindo IIIb-V (MESH:D009084), delirium (MESH:D003693), Postoperative Complications (MESH:D011183), hyperinsulinemia (MESH:D006946), postoperative nausea and vomiting (MESH:D020250), postoperative pain (MESH:D010149), Gastric Cancer (MESH:D013274), acute pancreatitis (MESH:D010195), alcoholic delirium (MESH:D000430), pain (MESH:D010146), anastomotic insufficiency (MESH:D000309), impaired glucose tolerance (MESH:D018149), hyperglycemic (MESH:D006944), ischemia (MESH:D007511), mitochondrial dysfunction (MESH:D028361), diabetes mellitus (MESH:D003920), -Dindo IIIb-V complication (MESH:C565555)
- **Chemicals:** rocuronium bromide (MESH:D000077123), Na+ (MESH:D012964), DMM (MESH:D020927), Blood glucose (MESH:D001786), phospholipids (MESH:D010743), lipopolysaccharides (MESH:D008070), sevoflurane (MESH:D000077149), Glucose (MESH:D005947), ondansetron (MESH:D017294), glycine (MESH:D005998), Xenon (MESH:D014978), Ca2+ (-), ropivacaine (MESH:D000077212), cortisol (MESH:D006854), ellagic acid (MESH:D004610), catecholamines (MESH:D002395), O2 (MESH:D010100), fentanyl (MESH:D005283), heparin (MESH:D006493), propofol (MESH:D015742), adrenaline (MESH:D004837), K+ (MESH:D011188)
- **Species:** Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028415/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13028415/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028415/full.md

---
Source: https://tomesphere.com/paper/PMC13028415